Charlie's Holdings, Inc. (OTCQB: CHUC, referred to as Charlie's) is a leading company in the high-quality nicotine vapor products industry. The company has recently released its operational data for the second quarter and first half of 2022, highlighting some impressive business performances.
The major financial highlights of Q2 2022 (compared to Q2 2021) are:
The company experienced a 36% growth in revenue, reaching $7.4 million, and an 8% increase in gross profit, reaching $2.8 million. The percentage of operating expenses decreased from 52% to 46% of revenue. Operating losses, which include $700,000 in research and development costs related to PMTA, increased by $400,000 to $600,000. The net loss was $600,000, while net income was $19.8 million.
The major financial highlights of the first half of 2022 (compared to the first half of 2021) were:
The company saw a 58% increase in revenue, reaching $15.5 million, and a 28% rise in gross profit, hitting $6.5 million. Operating expenses as a percentage of revenue decreased from 56% to 43%. Operating losses, including $800,000 in PMTA-related research and development costs, decreased by $200,000 to $200,000. The net income was $100,000 and the net loss was $400,000.
As of the quarterly operating results for June 30, 2022, compared to the same period last year:
Matt Montesano, the Chief Financial Officer of Charlie's Holdings, has reported that the company's strong momentum has continued into the second quarter and first half of 2022, with revenues increasing by 36% and 58% year-on-year, respectively. "We are continuing to diversify and expand Charlie's powerful product line, as seen in our new 12ml Pacha Syn disposable product line and updated Pacha Syn e-liquid series, both launched in the second quarter of 2022. At the same time, we are operating our business under strict financial controls, with operating expenses as a percentage of revenue further reduced to 46% in the second quarter, demonstrating this commitment.
The Chief Operating Officer of Charlie's, Ryan Stump, stated that their Pre-Market Tobacco Application (PMTA) for 2020 is among the few applications submitted to the FDA that have not received a marketing denial order (MDO) or a rejection file designation. They have invested an additional $700,000 in research and development towards the 2022 PMTA submission in the second quarter of this year to ensure compliance and offer reliable products to their customers. Before the FDA's deadline on May 14, they successfully submitted new PMTA for over 700 Pacha Syn products containing synthetic nicotine SKUs. Stump believes that their extensive investment in R&D and regulatory compliance efforts sets Charlie's apart from most of their competitors' PMTA submissions, putting them in the best position for success.
Charlie's CEO Henry Sicignano III explained, "As we refocus on our product development plans, sales team, marketing strategies, and strategic partnerships, Charlie's is growing. Over the next few months, we plan to launch a series of new disposable e-cigarettes with alternative cannabinoids... as well as new proprietary and innovative cannabinoid products by Charlie's. As a result of all these efforts, I am pleased to report that we are on track for our best year in company history.
Statement:
This article is compiled from third-party information, and is for industry discussion and learning purposes only.
This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of the article's content. The translation of this article is solely for the purpose of industry-related communication and research.
Due to limitations in the compiling level, the translated article may not fully reflect the original meaning. Please refer to the original article for accuracy.
2FIRSTS maintains complete alignment with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, or foreign-related statements and positions.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
